OverviewSuggest Edit

Outlook Therapeutics (formerly Oncobiologics) is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. The Company's current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. 

TypePublic
Founded2011
HQSouth Brunswick Township, US
Websiteoutlooktherapeutics.com
Employee Ratings2.9

Latest Updates

Employees (est.) (Sept 2019)14(-75%)
Revenue (FY, 2019)$8.1 M(+164%)
Share Price (Aug 2020)$1.3 (+2%)
Cybersecurity ratingAMore

Key People/Management at Outlook Therapeutics

Lawrence A. Kenyon

Lawrence A. Kenyon

President, Chief Executive Officer & Chief Financial Officer

Outlook Therapeutics Office Locations

Outlook Therapeutics has offices in South Brunswick Township and Cranbury Township
South Brunswick Township, US (HQ)
4260 US-1, Monmouth Junction
Cranbury Township, US
7 Clarke Dr, Cranbury
Show all (2)

Outlook Therapeutics Financials and Metrics

Outlook Therapeutics Revenue

Outlook Therapeutics's revenue was reported to be $8.15 m in FY, 2019
USD

Net income (Q2, 2020)

(5.7m)

EBIT (Q2, 2020)

(6.8m)

Market capitalization (7-Aug-2020)

160.1m

Closing stock price (7-Aug-2020)

1.3

Cash (31-Mar-2020)

4.7m

EV

162.7m
Outlook Therapeutics's current market capitalization is $160.1 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

3.0m3.8m3.1m8.1m

General and administrative expense

21.6m15.9m14.2m9.4m

R&D expense

33.1m23.8m18.5m23.8m

Operating expense total

54.7m39.7m32.7m33.2m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

994.9k494.9k303.1k303.1k303.1k771.9k771.9k771.9k1.1m641.1k583.8k

General and administrative expense

189.4k10.5m4.9m4.0m3.5m3.5m2.4m2.2m2.9m1.8m1.8m2.3m2.0m

R&D expense

4.1m12.0m13.3m4.2m4.2m402.4k5.2m5.8m8.4m6.5m4.4m5.8m4.4m

Operating expense total

4.3m22.5m18.2m8.2m7.7m4.0m7.6m8.0m11.3m8.3m6.2m8.2m6.3m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

2.4m3.2m1.7m8.0m

Accounts Receivable

20.0k

Prepaid Expenses

719.1k1.6m5.0m

Current Assets

5.7m3.9m3.3m13.5m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

2.8m13.6m2.1m81.0k139.9k13.8m5.9m11.8m227.7k155.5k14.0m1.3m4.7m

Accounts Receivable

504.9k3.7k

Prepaid Expenses

712.8k1.3m1.1m773.6k1.0m1.5m981.6k1.3m2.1m2.0m4.8m4.7m4.8m

Current Assets

4.1m14.9m3.2m854.7k1.2m15.3m6.9m13.1m2.3m2.1m18.8m6.5m9.5m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(53.3m)(38.8m)(30.1m)(34.5m)

Depreciation and Amortization

2.4m2.7m3.1m3.4m

Accounts Payable

(5.3m)5.7m(6.7m)(1.3m)

Cash From Operating Activities

(45.5m)(15.5m)(33.0m)(32.3m)
USDQ2, 2016

Debt/Equity

-0.1 x

Debt/Assets

0.1 x

Financial Leverage

-0.7 x
Show all financial metrics

Outlook Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Outlook Therapeutics Online and Social Media Presence

Embed Graph

Outlook Therapeutics News and Updates

Outlook Therapeutics Announces Closing of $1.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

MONMOUTH JUNCTION, N.J., July 17, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced the successful …

Thinking about buying stock in LATAM Airlines, Atossa Therapeutics, Outlook Therapeutics, Canopy Growth Corp, or Royal Caribbean Cruises?

NEW YORK, June 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LTM, ATOS, OTLK, CGC, and RCL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Outlook Therapeutics Provides Business Update and Reports Financial Results for the First Quarter of Fiscal Year 2020

First clinical trial results from the Phase 3 development program for ONS-5010 expected in six months First clinical trial results from the Phase 3 development program for ONS-5010 expected in six months

Outlook Therapeutics Announces Completion of Warrant Restructuring

CRANBURY, N.J., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has c…

Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2019

CRANBURY, N.J., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced business high…

Outlook Therapeutics stock rockets on heavy volume again, set to triple in 3 days

Shares of Outlook Therapeutics Inc. rocketed on heavy volume in premarket trade Monday, putting them on track to nearly triple in three days, in the wake of the biotechnology company's upbeat update on a drug trial and bullish analyst report. The stock 27% ahead of the open on premarket leading vol…
Show more

Outlook Therapeutics Frequently Asked Questions

  • When was Outlook Therapeutics founded?

    Outlook Therapeutics was founded in 2011.

  • Who are Outlook Therapeutics key executives?

    Outlook Therapeutics's key executives are Lawrence A. Kenyon.

  • How many employees does Outlook Therapeutics have?

    Outlook Therapeutics has 14 employees.

  • What is Outlook Therapeutics revenue?

    Latest Outlook Therapeutics annual revenue is $8.1 m.

  • What is Outlook Therapeutics revenue per employee?

    Latest Outlook Therapeutics revenue per employee is $581.9 k.

  • Who are Outlook Therapeutics competitors?

    Competitors of Outlook Therapeutics include OncoDNA, Ribon Therapeutics and Gamida Cell.

  • Where is Outlook Therapeutics headquarters?

    Outlook Therapeutics headquarters is located at 4260 US-1, Monmouth Junction, South Brunswick Township.

  • Where are Outlook Therapeutics offices?

    Outlook Therapeutics has offices in South Brunswick Township and Cranbury Township.

  • How many offices does Outlook Therapeutics have?

    Outlook Therapeutics has 2 offices.